thesis by claiming new cost-effective templates and silica source, a more safe environment for synthesis, reducing synthesis steps, duration of reaction, effective loading of low solubility drugs by magnetized nanocarriers, pathogen-specific release and development of novel photoluminescent rechargeable MSNs under mild conditions. It's a challenging task for researchers to successfully translate their prototypes to industries and make it feasible for commercialization. We can further work on excellent targeting concepts and architecture of MSNs for the increased opportunity in cancer theranostics.Mesenchymal stem cells (MSCs) are one of the most common types of adult stem cells. While MSCs are traditionally isolated from bone marrow, over the last few years, they have also been found in many other adult tissues such as liver, cord blood, placenta, dental pulp and adipose tissue. They have been investigated as a marvelous cell source for tissue regeneration and suggested as a therapy in non-autologous application, because of lack of MHC class II expression. For the past several decades, furthermore, MSCs show promise as a therapeutic strategy in medicine. Many advantages such as self-renewal, in vitro proliferation, rapid cell doubling capacity, easy of GMP manufacturing, antifibrotic, anti-apoptotic, anti-inflammation, immunomodulatory and immunosuppressive effects, and paracrine nature have been demonstrated in various pre-clinical studies and clinical evidences. The ability of MSCs to differentiate into different cell lineages, in addition to the lack of ethical problems in comparison with embryonic stem cells as well as induced Pluripotent Stem cells (iPSCs), have attracted much attention. click here Due to their unique features, various medical indications such as therapeutic medicine, tissue engineering, and cell therapy have allowed the development and flourishment of MSCs. The various different clinical trials were performed using MSCs for the treatment of a long list of diseases and disorders. Results of these clinical studies have demonstrated the capability of MSCs to be used for the treatment of dermatological, musculoskeletal, neurological, cardiovascular, respiratory, renal, gastroenterological and urological conditions, etc. Chronic hyperglycaemia and related complications involving peripheral nerves in diabetes are one of the most severe microvascular complications with an average prevalence of 50-60%. Diabetic neuropathy is among the vascular disorders of diabetes, the most debilitating and crippled, lethal condition impacting patients's quality of life. In present review article, several hypothesis associated with pathogenesis of Diabetic Peripheral Neuropathy (DPN) have been introduced, out of which metabolic pathway associated with polyol pathway, oxidative stress, production of reactive oxygen species (ROS) amplified under chronic hyperglycemic conditions and activation of transcription factor Nuclear factor-κB (NF-κB). The review article also possesses pathogenetic and pharmacologic treatments along with other treatments including acupressure, lidocaine and capsaicin for DPN. It may be concluded that we can combat the pathogenesis of DPN with different suggested treatments.It may be concluded that we can combat the pathogenesis of DPN with different suggested treatments. Patients with type 2 diabetes mellitus (T2DM) are at significantly higher risk of developing cardiovascular disease (CVD). There is scarcity of literature reviews that describes and summarises T2DM patients' knowledge and perception about CVD prevention. To describe and summarise the assessment of knowledge and perceptions about CVD risk and preventive approaches among patients with T2DM. A scoping review methodology was adopted, and three scientific databases, Google Scholar, Science Direct and PubMed were searched using predefined search terms. A multistage screening process that considered relevancy, publication year (2009-2019), English language, and article type (original research) was followed. We formulated research questions focused on the assessment of levels of knowledge and perceptions of the illness relevant to CVD prevention and the identification of associated patients' characteristics. A total of 16 studies were included. Patients were not confident to identify CVD risk and other clinicthe understanding of CVD risk among patients with T2DM. The findings necessitate educational initiatives to boost CVD prevention among patients with T2DM. Furthermore, these should be individualised based on patients' characteristics and knowledge gaps, disease duration and estimated CVD risk.In this review, authors focus mostly on the various synthetic strategies developed so far for 1,2,3- triazole scaffold and its derivatives via different approaches such as metal-free, metal assisted or bimetallic. A brief overview of applications of the very important 1,2,3-triazole scaffold along with pharmacological activity is also discussed. Synthetic strategies are updated until June 2020.Ischemic stroke is one of the main causes of mortality and disability worldwide. However, efficient therapeutic strategies are still lacking. Stem/progenitor cell-based therapy, with its vigorous advantages, has emerged as a promising tool for the treatment of ischemic stroke. The mechanisms involve new neural cells and neuronal circuitry formation, antioxidation, inflammation alleviation, angiogenesis, and neurogenesis promotion. In the past decades, in-depth studies have suggested that cell therapy could promote vascular stabilization and decrease blood-brain barrier (BBB) leakage after ischemic stroke. However, the effects and underlying mechanisms on BBB integrity induced by the engrafted cells in ischemic stroke have not been reviewed yet. Herein, we will update the progress in research on the effects of cell therapy on BBB integrity after ischemic stroke and review the underlying mechanisms. First, we will present an overview of BBB dysfunction under the ischemic condition and cells engraftment for ischemic treatment. Then, we will summarize and discuss the current knowledge about the effects and underlying mechanisms of cell therapy on BBB integrity after ischemic stroke. In particular, we will review the most recent studies in regard to the relationship between cell therapy and BBB in tissue plasminogen activator (t-PA)-mediated therapy and diabetic stroke.